12031a h89 mce cat (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress 12031a h89 mce cat
12031a H89 Mce Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 226 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h+89/H-89/pm42585016-166-130-132
Average 97 stars, based on 226 article reviews

12031a h89 mce cat - by Bioz Stars, 2026-09

97/100 stars

Images

Inhibition:

Article Title: CaRPOOL: a pooled calcium‑recording CRISPR screening platform identifies CCR7 as a modulator of cellular osmomechanosensing
Article Snippet: .. For adenylyl cyclase or protein kinase A inhibition, cells were seeded and incubated overnight, then treated with SQ22536 (100 μM; MCE, HY‐100396) or H‐89 (10 μM; MCE, HY‐15979) for 2 h prior to experiments. .. For adenylyl cyclase activation, cells were treated with forskolin (20 μM; SelleckChem, S2449) for 5 s immediately before stimulation.

Incubation:

Control:

Article Title: Activation of the TGR5/cAMP/PKA/CREB axis in cholangiocytes mediates epithelial-mesenchymal transition and fibrosis in hepatolithiasis
Article Snippet: When cell confluence reached approximately 70–80%, cells were treated with 500 μM taurodeoxycholic acid (TDCA; Sigma, Cat# T4009) for 24 h to establish a bile acid-induced biliary fibrosis model. Each condition was tested in triplicate, and the entire experiment was independently repeated twice to ensure reproducibility and data reliability. .. Based on the TDCA-induced cholangiocyte fibrosis cell model, additional pharmacological intervention groups were established as follows (3 technical replicates per group; each experiment was independently repeated twice): Control group (Control): no TDCA induction and no drug treatment; Model group (Model): treated with 500 μM TDCA for 24 h; Forskolin treatment group (Model + Forskolin): cells were co-treated with 500 μM TDCA and 50 μM forskolin (HY-15371, MCE) for 24 h [ ]; H-89 treatment group (Model + H-89): cells were co-treated with 500 μM TDCA and 100 μM H-89 (HY-15979, MCE) for 24 h [ ]; Combined treatment group (Model + Forskolin + H-89): cells were co-treated with 500 μM TDCA, 50 μM forskolin, and 100 μM H-89 for 24 h; TGR5 inhibitor combination group (Model + SBI-115 + Forskolin): cells were co-treated with 500 μM TDCA, 10 μM SBI-115 (TGR5 inhibitor), and 50 μM forskolin for 24 h. ..

Article Title: Activation of the TGR5/cAMP/PKA/CREB axis in cholangiocytes mediates epithelial-mesenchymal transition and fibrosis in hepatolithiasis.
Article Snippet: When cell 244 confluence reached approximately 70-80%, cells were treated with 500 μM taurodeoxycholic acid 245 (TDCA; Sigma, Cat# T4009) for 24 hours to establish a bile acid-induced biliary fibrosis model. 246 Each condition was tested in triplicate, and the entire experiment was independently repeated twice 247 to ensure reproducibility and data reliability. .. 248 249 AR TIC LE IN PR ES S H-89 and forskolin treatment 250 Based on the TDCA-induced cholangiocyte fibrosis cell model, additional pharmacological 251 intervention groups were established as follows (3 technical replicates per group; each experiment 252 was independently repeated twice):Control group (Control): no TDCA induction and no drug 253 treatment; Model group (Model): treated with 500 μM TDCA for 24 h; Forskolin treatment group 254 (Model + Forskolin): cells were co-treated with 500 μM TDCA and 50 μM forskolin (HY-15371, 255 MCE) for 24 h [19]; H-89 treatment group (Model + H-89): cells were co-treated with 500 μM 256 TDCA and 100 μM H-89 (HY-15979, MCE) for 24 h [20]; Combined treatment group (Model + 257 Forskolin + H-89): cells were co-treated with 500 μM TDCA, 50 μM forskolin, and 100 μM H-89 258 for 24 h; TGR5 inhibitor combination group (Model + SBI-115 + Forskolin): cells were co-treated 259 with 500 μM TDCA, 10 μM SBI-115 (TGR5 inhibitor), and 50 μM forskolin for 24 h. 260 261 CCK-8 Assay 262 HIBECs were digested and seeded into 96-well plates at a density of 1 × 104 cells per well, with 263 three technical replicates per group. .. After incubation at 37°C with 5% CO2 for 4-6 hours to allow 264 adherence, cells were treated with various concentrations of the following compounds: TDCA 265 (Sigma, Cat# T4009; 250, 500, 1000 μM), TGR5 agonist hyodeoxycholic acid (HDCA; 266 MedChemExpress, Cat# HY-113554; 50, 100, 200 μM), and TGR5 inhibitor SBI-115 (Sigma, Cat# 267 SML1790; 5, 10, 20 μM).

Injection:

Article Title: Therapeutic effects of alprostadil on CCl 4 -induced hepatic fibrosis in rats and investigation of its molecular mechanisms.
Article Snippet: Extended author information available on the last page of the article Abstract Hepatic fibrosis (HF) is driven by hepatic stellate cell (HSC) activation.. Although cyclic adenosine monophosphate (cAMP) is a key antifibrotic signal, whether pharmacological cAMP elevation acts through protein kinase A (PKA) or exchange protein directly activated by cAMP 1 (EPAC1) remains unclear.. Alprostadil (PGE1) elevates intracellular cAMP, but its antifibrotic mechanism is undefined.

CCK-8 Assay:

Reverse Transcription:

Real-time Polymerase Chain Reaction:

Lysis:

Protease Inhibitor:

Bicinchoninic Acid Protein Assay:

SDS Page:

Immunoprecipitation:

Magnetic Beads:

Enzyme-linked Immunosorbent Assay:

AST Assay:

Western Blot:

other:

Article Title: Propranolol alleviates cerebral infarction through the β2-AR-mediated ERK/NLRP3 pathway
Article Snippet: H-89 , MCE , Cat# HY-15979A.

Review